Showing posts with label pregnancy. Show all posts
Showing posts with label pregnancy. Show all posts

Sunday, September 22, 2013

New asthma treatment guidelines.(DRUGS, PREGNANCY, AND LACTATION): An article from: Internal Medicine News




This digital document is an article from Internal Medicine News, published by International Medical News Group on May 15, 2005. The length of the article is 835 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.


Citation Details
Title: New asthma treatment guidelines.(DRUGS, PREGNANCY, AND LACTATION)
Author:



List Price: $ 5.95


Price: $ 5.95


Information on Asthma from Gooasthma.info Choices including causes, symptoms, diagnosis, risks and treatment and with links to other useful resources.
New asthma treatment guidelines.(DRUGS, PREGNANCY, AND LACTATION): An article from: Internal Medicine News


Inhaled corticosteroids and fetal growth.: An article from: Internal Medicine News





This digital document is an article from Internal Medicine News, published by Thomson Gale on April 15, 2006. The length of the article is 823 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.


Citation Details
Title: Inhaled corticosteroids and fetal growth.
Author: Gideon Koren
Publication: Internal Med



List Price: $ 5.95


Price: $ 5.95


Information on Asthma from Gooasthma.info Choices including causes, symptoms, diagnosis, risks and treatment and with links to other useful resources.
Inhaled corticosteroids and fetal growth.: An article from: Internal Medicine News


More Corticosteroids Asthma Products



Orignal From: New asthma treatment guidelines.(DRUGS, PREGNANCY, AND LACTATION): An article from: Internal Medicine News

Friday, September 20, 2013

MANAGEMENT OF ASTHMA IN PREGNANCY



 INTRODUCTION :     

       Asthma is defined as a chronic inflammatory disease of the airway that is manifested by hyper responsiveness of airway to a wide variety of stimuli. It tends to be an episodic disease with exacerbations of reversible airway narrowing that are characterized clinically by coughing, wheezing and shortness of breath.

       Asthma is probably the most common and potentially life threatening disorder to occur in pregnancy. The worldwide incidence is about 1 to 4%. It complicates in 0.5 to 1.5% of pregnancies and status asthmaticus complicates in 0.2%. In 20% the condition improves, in 30% cases it deteriorates and in 50% cases it remains unchanged.

       In pregnancy, bronchodialator action is due to progesterone and cortisol and bronchoconstrictor action is due to reduced residual volume and increased PGF2 α.




 
EFFECTS OF PREGNANCY ON ASTHMA :

        There is no evidence that pregnancy has predictable effect on underlying asthma. 1/3rd of asthmatic women can expect worsening of disease at sometime during pregnancy.  There is 18% increase in exacerbation of asthma following caesarian delivery compared with vaginal delivery.




EFFECTS OF ASTHMA ON PREGNANCY :


       When severe asthma can affect pregnancy outcome . It may lead to abortions preterm labour, LBW, neonatal hypoxia etc.


       There is a significant correlation between maternal pulmonary function and  foetal birth weight. 

       Uncontrolled asthma has maternal risks and  maternal deaths may be associated with status asthmaticus.

       It may lead to life threatening complications like- pnuemothorax, pneumomediastenum, acute cor pulmonale, cardiac arrhythmias and  muscle fatigue with respiratory arrest.






PATHOPHYSIOLOGY :

Allergens, respiratory infections, environmental pollutants, occupational exposure, cold air, emotional stress, strenuous exercise, aspirin and β blockers can precipitate asthma.


                                                                           Acted by primary mediators like histamines


                                                                           and  secondary mediators like PGs,

                                                                           thromboxanes and leukotrienes.





Mucus hypersecretion and mucosal edema



CLINICAL  COURSE :


Clinically,

It may range from


Mild wheezing             ___                                        severe bronchospasm


                                                                                        |           


Respiratory failure



 |




Severe hypoxaemia



 |



          DEATH










Functionally


                 Acute broncospasm( airway obstruction and reduced airflow)



                                                       |




                                           Increased breathing



                                                       |




                           Chest tightness/ wheezing/ breathlessness



                                                    |




                                           Altered oxygenation



                                                      |



                Ventilation perfusion mismatching and airway narrowing














CLINICAL STAGES OF ASTHMA











































       Stage


         PO2


       PCO2


         pH


     FEV1


Mild respiratory alkalosis


      Normal










65 – 80




Respiratory alkalosis














50 – 64




Danger  zone








      normal


      Normal


35 – 49




Respiratory acidosis














<35










FEV – forced expiratory volume in 1 second








 






FOETAL EFFECTS :






Maternal alkalosis leads to fetal hypoxaemia well before maternal oxygenation is compromised.


Thus the fetus may be seriously compromised before maternal distress is severe.

This underscores the need for aggressive management of all pregnant women with acute asthma.

Therefore fetal response in effect becomes an indicator of maternal compromise .
















CLINICAL EVALUATION :

 Signs :-


1) 1   Labored breathing



2)  2  Tachycardia



3)   3 Pulsus  paradoxus



4) 4   Prolonged expiration and use of accessory muscles of respiration




Fatal signs:-


1)   1 Central cyanosis



2)    2 Altered consciousness




Investigations:-


1)    1 ABG  analysis



2)   2  PEFR < 60% of baseline



3)   3  FEV1 < 20% suggestive of severe distress



4) 4    PO2 < 70 mm of Hg at sea level



5) 5   PCO2 > 35 mm of Hg at sea level



6)  6   PCO2 > 40 mm of Hg in pregnancy is suggestive of respiratory failure.



7)   7  pH < 7.35 (indication of hyperventilation and CO2 retention)



P     



Preconceptional –




P


p    possibility of child becoming asthmatic is 4%

If    If 1 parent is asthmatic, the possibility is 8 to 10%

If     both parents are asthmatic, the possibility is 30%










A  Pregnancy –

A  A STEP WISE PLAN is recognized by the

U.U. S. National Asthma Education And Prevention Programme       &

     British  Thoracic  Society.

A     As told earlier, patient education is of utmost importance.


1)    1.Patient must measure PEFR  twice daily.



2)    2.Use of proper inhaler



3)  3.  Patient is given a written management plan



4) 4.   Use of impermeable pillows



5)   5. Avoid pets at home



6) 6.   No carpets in bedrooms



7) 7.   Avoid cigarette smoke


If   If PEFR reduces by 20% then step up the therapy and patient must see a physician

If    If  PFER reduces by 50% its an emergency and needs hospitalization.




    TREATMENT OF ASTHMA HAS TWO MAJOR GROUPS


  



           RESCUE AGENTS                                                 MAINTENANCE AGENTS

     Relieve bronchospasm                                          treat airway inflammation                                              

      Eg: β2 agonists                                                      Eg: steroids, mast cell stabilizers,

and  ipratropium                                                     methyl xanthenes, leukotriene  






                    
STEP WISE THERAPY :-



   





























     Category


             Criteria


                    Step therapy


Mild intermittent

PEFR>80%

Variability<20%


-symptoms occur twice a week

-at night twice a month

-exacerbations last for hours to a few days

-asymptomatic in between two episodes


-no daily treatment required

-inhalation of β2 adrenergic agonists as needed


Mild persistant

PEFR >80%

Variability 20-30%



-symptoms occur more than twice a week


-night symptoms more than twice a month

-exacerbations may affect daily activity


- inhalation of β2 adrenergic agonists as needed

-and daily treatment with inhaled chromolyn or nedochromil or low dose corticosteroids or theophylline


Moderate persistant

PEFR 60-80%

Variability >30%


-symptoms occur daily

-night symptoms > once a week




-inhalation of β2 adrenergic agonists as needed

-and daily treatment with low to medium dose corticosteroids

-and daily treatment with salmeterol/theophylline preparation


Severe persistant

PEFR <60%

Variability >30%


-continual symptoms that limit activity

-frequent night symptoms an d actual exacerbations


-inhalation of β2 adrenergic agonists as needed

-and daily treatment with high dose corticosteroids

-and daily treatment with salmeterol/theophylline preparation

-and daily or alternate day treatment with systemic prednisolone


                                                                      




If plan fails treatment with prednisolone orally for 5 to 10 days.






Intra partum :-

During labour ,exacerbation is rare because of natural outpouring of endogenous steroids and epinephrine associated with stress of delivery.


1)         1;Clinical evaluation of the patient in labour may be inaccurate to predict the severity.



2)          2:Stress dose corticosteroids must be given during labour if the patient had steroids within the previous 4 weeks . HYDROCORTISONE 100mg I.V. 8 hrly.



3)         3:Opoid analgesics must be avoided as they cause bronchconstriction and respiratory depression. FENTANYL is preferred as it is non histaminic releasing narcotic over meperidine and morphine.



4)        4: SYNTOCINON is preferred over ergometrine, because the latter causes bronchoconstriction.



5)   5: PGF2α should not be used as it precipitates bronchospasm.



6)  6:  PGE1 and PGE2 can be used locally for induction of labour or abortion.



7)  7:  EPIDURAL ANAESTHESIA is preferable to G.A. because of risk of atelectasis and chest infection by latter.



8) 8:   If G.A. is given then bronchodialators like HALOTHANE and KETAMINE should be used.



9)    9:ABG analysis may be needed to assess oxygenation, ventilation and acid-base status.(PCO2 > 35mmHg and pH>7.35 indicates CO2 retension)



      10) THEOPHYLLINE is used as an adjunct for nocturnal asthma.










Post natal :-       


1)    1:Post natal physiotherapy



2) 2:   Encourage breast feeding



3)  3:  Restart maintenance drug therapy



4)  4:  Encourage respiratory therapy to prevent atelectasis



5)    5:BARRIER CONTRACEPTIVES must be encouraged



6)    6:Advice VASECTOMY for terminal measures












Dr. Arpita Masalia

M.S. RESIDENT(GYNAEC)

P.G. SCHOLAR







Wednesday, September 18, 2013

0 Incidence and risk factors for exacerbations of asthma during pregnancy



Incidence and risk factors for exacerbations of asthma during pregnancy





Review


(917) Total Article Views





Authors: Ali Z, Ulrik CS


Published Date May 2013 Volume 2013:6 Pages 53 – 60
DOI: http://dx.doi.org/10.2147/JAA.S43183
















Zarqa Ali, Charlotte Suppli Ulrik


Department of Pulmonary Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark


Background: Asthma is one of the most common chronic diseases among pregnant women. Acute exacerbations of asthma during pregnancy have an unfavorable impact on pregnancy outcome. This review provides an overview of current knowledge of incidence, mechanisms, and risk factors for acute exacerbations of asthma during pregnancy.
Methods: A narrative literature review was carried out using the PubMed database.
Results: During pregnancy, up to 6% of women with asthma are hospitalized for an acute exacerbation. The maternal immune system is characterized by a very high T-helper-2:T-helper-1 cytokine ratio during pregnancy and thereby provides an environment essential for fetal survival but one that may aggravate asthma. Cells of the innate immune system such as monocytes and neutrophils are also increased during pregnancy, and this too can exacerbate maternal asthma. Severe or difficult-to-control asthma appears to be the major risk factor for exacerbations during pregnancy, but studies also suggest that nonadherence with controller medication and viral infections are important triggers of exacerbations during pregnancy. So far, inconsistent findings have been reported regarding the effect of fetal sex on exacerbations during pregnancy. Other risk factors for exacerbation during pregnancy include obesity, ethnicity, and reflux, whereas atopy does not appear to be a risk factor.
Discussion: The incidence of asthma exacerbations during pregnancy is disturbingly high. Severe asthma – better described as difficult-to-control asthma – nonadherence with controller therapy, viral infections, obesity, and ethnicity are likely to be important risk factors for exacerbations of asthma during pregnancy, whereas inconsistent findings have been reported with regard to the importance of sex of the fetus.


Keywords: acute exacerbations, pregnancy, asthma severity, incidence, risk factors



Post to:
CannoteaCiteulikeDel.icio.usFacebookLinkedInTwitter